Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

The expression level of microRNA-122 in patients with type 2 diabetes mellitus in correlation with risk and severity of coronary artery disease

The Egyptian Journal of Internal Medicine volume 31, pages 593–601 (2019)Cite this article

Abstract

Background

Type 2 diabetes mellitus (T2DM) has reached epidemic proportions worldwide. Coronary artery disease (CAD) is one of the most important causes of mortality worldwide. MicroRNAs (miRNAs) modulate gene expression and is involved in the pathogenesis of T2DM and CAD. The objective of the current study was to explore the expression pattern of miR-122 in T2DM with or without CAD. Moreover, we aimed to evaluate the association between miR-122 and risk and severity of CAD in T2DM.

Participants and methods

This cross-sectional controlled study enrolled 130 patients with T2DM and 110 control group. The enrolled diabetic patients were classified into two groups: seventy patients without CAD and 60 patients without CAD. All patients were investigated using a 12-lead standard ECG, echocardiography, and coronary arteriography. The serum MiR-122 expression profile was measured using quantitative real-time (qRT) PCR.

Results

miRNA-122 expression levels were significantly higher in T2DM, in particular patients with T2DM with CAD, compared with the control group. Interestingly, miRNA-122 expression levels were positively correlated with cardiometabolic risks and severity of coronary occlusion. Linear regression analysis test showed that miRNA-122 were independently correlated with high-density lipoprotein, ejection fraction, and uric acid. The power of miRNA-122 expression level to diagnose T2DM among studied participants was evaluated using receiver operating characteristic. The area under curve was 0.997 (95% confidence interval=0.993–1.00), with sensitivity of 96.9% and specificity of 99%, and regarding the power for differentiating patients with T2DM with CAD from patients with T2DM without CAD, the area under curve was 0.832 (95% confidence interval=0.763–0.902), with sensitivity of 93.3% and specificity of 96.86%.

Conclusion

The miRNA-122 expression levels were higher in the T2DM group compared with controls, in particular patients with CAD. The higher levels of miR-122 expression were strongly correlated with cardiometabolic risk factors and severity of coronary occlusion. Therefore, miR-122 expression levels seem to be a noninvasive biomarker for CAD.

References

  1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378:31–40.

    Article  CAS  Google Scholar 

  2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD Blaha MJ, et al. Heart Disease and Stroke Statistics—2014 Update: A Report From the American Heart Association. Circulation 2014; 129: e28–e292.

    Article  Google Scholar 

  3. Preis SR, Pencina MJ, Hwang SJ. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation 2009; 120:212–220.

    Article  Google Scholar 

  4. Di Angelantonio E, Kaptoge S, Wormser D. for the Emerging Risk Factors Collaboration Association of cardiometabolic multimorbidity with mortality. JAMA 2015; 314:52–60.

    Article  Google Scholar 

  5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281–297.

    Article  CAS  Google Scholar 

  6. Guay C, Regazzi R. Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol 2013; 9:513–521.

    Article  CAS  Google Scholar 

  7. Gao W, He HW, Wang ZM, Zhao H, Lian XQ, Wang YS, et al. Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis 2012; 11:55.

    Article  CAS  Google Scholar 

  8. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (- delta delta C (T)) methods. Methods 2001; 25:402–408.

    Article  CAS  Google Scholar 

  9. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Steen Z, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008; 117:1945–1954.

    Article  CAS  Google Scholar 

  10. Gupta SK, Bang C, Thum T. Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet 2010; 3:484–488.

    Article  CAS  Google Scholar 

  11. Willeit P, Skroblin P, Moschen AR, Yin X, Kaudewitz D, Zampetak A, et al. Circulating MicroRNA-122 is associated with the risk of new-onset metabolic syndrome and type 2 diabetes. Diabetes 2017; 66:347–357.

    Article  CAS  Google Scholar 

  12. Fernández-Hernando C, Ramírez CM, Goedeke L, Suárez Y. MicroRNAs in metabolic disease. Arterioscler Thromb Vasc Biol 2013; 33:178–185.

    Article  Google Scholar 

  13. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005; 438:685–9.

    Article  Google Scholar 

  14. Esau C, Davis S, Murray SF, Bennett CF, Bhanot S, Monia BP, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3:87–98.

    Article  CAS  Google Scholar 

  15. Elmén J, Lindow M, Schütz S, Lawrence M, Petri A, Obad S, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452:896–899.

    Article  Google Scholar 

  16. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327:198–201.

    Article  CAS  Google Scholar 

  17. Dong S, Cheng Y, Yang J, Li J, Liu X, Wang X, et al. MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 2009; 284:29514–29525.

    Article  CAS  Google Scholar 

  18. D’Alessandra Y, Devanna P, Limana F, Straino S, DiCarlo A, Brambilla PG, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010; 31:2765–2773.

    Article  Google Scholar 

  19. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010; 31:659–666.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, 44519, Egypt

    Nearmeen M. Rashad MD, Tamer M. Ezzat & Mohammed S. Yousef

  2. Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Reem M. Allam

  3. Department of Cardiology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Mohamad H. Soliman

Authors
  1. Nearmeen M. Rashad MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tamer M. Ezzat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Reem M. Allam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohamad H. Soliman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohammed S. Yousef
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nearmeen M. Rashad MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rashad, N.M., Ezzat, T.M., Allam, R.M. et al. The expression level of microRNA-122 in patients with type 2 diabetes mellitus in correlation with risk and severity of coronary artery disease. Egypt J Intern Med 31, 593–601 (2019). https://doi.org/10.4103/ejim.ejim_125_19

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_125_19

Keywords